ArticleInternational journal of molecular sciences2025
Investigating the Role of Peroxisomes in Regulating Breast Cancer Stem Cell Mechanisms.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global pattern and evolution of PPARγ in breast cancer: a 25-Year bibliometric and visualized knowledge map analysis.Frontiers in oncology · 2026Pooled it
- Ferroptosis in Breast Cancer: Molecular Insights and Therapeutic Strategies.Frontiers in bioscience (Landmark edition) · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cancer and ageing remain major challenges for humanity, requiring innovative solutions. While the role of mitochondria in cancer and ageing has been extensively studied, peroxisomes have received comparatively little attention in this context. In our study, we investigated the impact of peroxisomes on cancer stemness. We systematically analysed the metabolic differences between MCF-7 cells with low- and high-peroxisome levels. Briefly, MCF-7 cells were stably transduced with GFP- and RFP-fluorescent reporters that were targeted to peroxisomes, by addition of a C-terminal SKL (Serine-Lysine-Leucine) peroxisomal targeting signal. To independently validate our observations, MCF-7 cells were also treated with Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist that enhances peroxisome levels. Key parameters examined included cancer stemness, levels of reactive oxygen species (ROS), cell division dynamics, autophagy activity, the DNA damage response, susceptibility to ferroptosis, mitochondrial respiration, and aerobic glycolysis in cells with low- and high-peroxisome profiles. Our results demonstrated that elevated peroxisome levels significantly decrease the capacity of breast cancer stem cells (BCSCs) to form mammospheres or colonies, thus reducing their stemness potential. In high-peroxisome cells, Mammosphere formation was reduced by approximately 50%, and colony formation by 80% compared to low-peroxisome cells. This decline in stemness was accompanied by an approximately one-and-a-half-fold increase in ROS levels and a five-fold increase in lipid peroxidation, reflecting increased mitochondrial lipid peroxidation and ferroptosis. Continued research is, however, essential to further validate these findings and to elucidate the underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.